loading page

  • +1
  • Femke Aarsen,
  • MarieLise van Veelen-Vincent,
  • Marita Partanen,
  • Coriene Catsman-Berrevoets
Femke Aarsen
Prinses Máxima Centrum voor Kinderoncologie

Corresponding Author:[email protected]

Author Profile
MarieLise van Veelen-Vincent
Erasmus MC Sophia
Author Profile
Marita Partanen
Prinses Máxima Centrum voor Kinderoncologie
Author Profile
Coriene Catsman-Berrevoets
Erasmus MC Sophia
Author Profile


Objective: 7-50% of children with medulloblastoma (MB) develop postoperative cerebellar mutism syndrome (pCMS). pCMS has a short-term negative impact on intelligence, but results on long-term outcomes are contradictory. The aim of this study was to assess long-term effects of pCMS in MB patients on aspects of intelligence (IQ) and its perioperative risk factors. Methods: In this single centre retrospective cohort study, 31 children with MB were included of which 14 had pCMS. Peri-operative risk factors included brainstem invasion, vermis incision, pre-and post-operative hydrocephalus, tumor size, duration and severity of pCMS, neurological symptoms on day 10 after surgery, mean body temperature (BT) on days 1-4 post surgery, and age at resection. Age appropriate Wechsler Intelligence tests were assessed within a structured follow up programme. Results: No significant differences in IQ scores were found between pCMS and non pCMS groups. The pCMS group had a clinically relevant difference of 10 points when compared to age norms on verbal IQ (VIQ). Bilateral pyramidal and swallowing problems were risk factors for lower performance in this group. In the overall group, tumor size, younger age at surgery, and raised mean BT on days 1-4 post-surgery were negatively correlated with aspects of IQ. Conclusions: We found a clinically significant reduction of VIQ in the pCMS patient group. pCMS patients with a larger tumor size, younger age at surgery, a higher mean BT in the first days after surgery, bilateral pyramidal symptoms, and swallowing problems 10 days post-surgery are more at risk for VIQ deficits at long-term.
30 Apr 2021Submitted to Pediatric Blood & Cancer
30 Apr 2021Submission Checks Completed
30 Apr 2021Assigned to Editor
03 May 2021Reviewer(s) Assigned
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending
08 Jun 2021Editorial Decision: Revise Major
09 Aug 20211st Revision Received
09 Aug 2021Assigned to Editor
09 Aug 2021Submission Checks Completed
11 Aug 2021Reviewer(s) Assigned
10 Sep 2021Review(s) Completed, Editorial Evaluation Pending
11 Sep 2021Editorial Decision: Revise Minor
29 Oct 20212nd Revision Received
29 Oct 2021Submission Checks Completed
29 Oct 2021Assigned to Editor
01 Nov 2021Reviewer(s) Assigned
16 Nov 2021Review(s) Completed, Editorial Evaluation Pending
18 Nov 2021Editorial Decision: Accept